Registered Nurse Birthplace/OB

BIDMC OB/GYN program ranked #4 in the nation by U.S. News & World Report. Beth Israel Deaconess Medical Center's (BIDMC) Department of Obstetrics and Gynecology has been ranked #4 in the nation for Obstetrics & Gynecology care in U.S. News & World Report's 2026-2027 Best Hospitals rankings. The department was also recognized as Nationally High Performing in Gynecologic Cancer Surgery. "This recognition belongs to our entire department. Every day, our team brings our core values of humanity, excellence, and equity to life through the care we provide," said Blair Wylie, MD, MPH, Chair of the Department of Obstetrics and Gynecology at BIDMC. "From routine care to the most complex needs, our patients trust us to be with them at every stage of their journey. It is a privilege to care for them, and they are the reason this work and this recognition are so meaningful." The U.S. News & World Report recognition is part of a broader showing for BIDMC in this year's rankings. The hospital placed among the top 50 hospitals nationwide in eight specialties, and was named the #3 best hospital in the Boston region and #3 best hospital in Massachusetts. Across its specialties and procedures and conditions, BIDMC received 20 high-performing ratings in total. U.S. News evaluated nearly 4,500 hospitals across 14 adult specialties and 23 procedures and conditions for this year's rankings; fewer than half earned recognition in any of the 37 areas of care assessed. To determine the Best Hospitals rankings, U.S. News analyzed each hospital's performance using objective measures such as risk-adjusted mortality rates, preventable complications, and patient experience, drawing on data from more than 800 million patient care records. More information on the U.S. News & World Report Best Hospitals rankings, including the full specialty rankings and procedures and conditions methodologies, is available at health.usnews.com/best-hospitals.

Beth Israel Deaconess Medical Center nationally recognized by U.S. News & World Report. August 05, 2026 BIDMC named in top three hospitals in Massachusetts. Boston, MA - Beth Israel Deaconess Medical Center (BIDMC) has been recognized for its high-quality care by U.S. News & World Report's 2026-2027 Best Hospitals edition, placing in the top 50 hospitals nationwide in eight specialties. BIDMC was ranked in the top 10 nationwide for two of those specialties: obstetrics & gynecology and diabetes & endocrinology. BIDMC was also named as the #3 best hospital in the Boston Metro Area region and #3 best hospital in Massachusetts. "Being again nationally recognized by U.S. News & World Report reflects the high-quality care teams across BIDMC provide to patients and their families," said Pete Healy, president, BIDMC & divisional president, Metro Boston, Beth Israel Lahey Health. "I am thankful for the commitment of our physicians, nurses, and staff to excellent and compassionate care." The eight specialties that BIDMC received national rankings include: * Obstetrics & Gynecology * Diabetes & Endocrinology * Gastroenterology & GI surgery * Pulmonology & Lung surgery * Cancer Care * Neurology & Neurosurgery * Heart & Vascular * Geriatrics The hospital received 20 high-performing ratings across specialties and procedures & conditions, including aortic valve surgery; colon cancer surgery; ear, nose & throat surgery; gynecological cancer surgery; heart bypass surgery; heart failure; kidney failure; leukemia, lymphoma & myeloma; lung cancer surgery; prostate cancer surgery; stroke; and urology. U.S. News evaluated nearly 4,500 hospitals across 14 adult specialties and 23 procedures and conditions; less than half earned recognition in any of those 37 areas of care. To determine the Best Hospitals, U.S. News analyzed each hospital's performance based on objective measures such as risk-adjusted mortality rates, preventable complications and patient experience. The Best Hospitals Specialty rankings methodology and Procedures & Conditions ratings methodology measure patient outcomes using data from over 800 million records of patient care. About Beth Israel Deaconess Medical Center. Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education. Director of Media Relations Sarah finlaw. Please note: The contact information above is for journalists and news media only. For patient care and all other inquiries, please contact your doctor or BIDMC directly.

Newly approved pill cuts LDL cholesterol levels by more than half. News briefs. July 20, 2026 * Reviewed by Robert H. Shmerling, MD, Senior Faculty Editor, Harvard Health Publishing; Editorial Advisory Board Member, Harvard Health Publishing A new pill that dramatically lowers harmful LDL cholesterol may be a good option for people who can't tolerate statins or who haven't lowered their LDL enough despite their current treatment with cholesterol-lowering drugs. Approved by the FDA in July 2026, enlicitide (Lipfendra) is the first oral version of a class of drugs known as PCSK9 inhibitors. These drugs work by mimicking the effect of a naturally occurring variant in the PCSK9 gene that leads to very low LDL levels. But the original drugs - which are given by injection once or twice a month - aren't widely used. Some people aren't comfortable giving themselves an injection. Also, most insurance companies won't cover the cost (which range from $200 to $500 or more per month) until a person has tried other therapies without success. Enlicitide is a daily pill that must be taken on an empty stomach with a sip of water, black coffee, or plain tea. It lowers LDL by nearly 60%, which is similar to the injectable PCSK9 drugs. Less than 10% of users experienced either dizziness or diarrhea, the two most common side effects. A month's supply will cost about $300; for now, insurance coverage remains unclear. You might also be interested in... Managing Your Cholesterol. Managing Your Cholesterol offers up-to-date information to help you or a loved one keep cholesterol in check. The report spells out what are healthy and unhealthy cholesterol levels, and offers specific ways to keep cholesterol in line. It covers cholesterol tests and the genetics of cholesterol. The report also focuses on treatments based on the latest scientific evidence, including the pros and cons of statins and other medications, and provides the lowdown on other substances advertised to lower cholesterol. Managing Your Cholesterol can also help you work with your doctor to individualize your treatment. The drug might be especially helpful for people whose LDL remains above recommended levels, despite taking cholesterol-lowering drug such as statins. The 2026 cholesterol guidelines recommend that people who've had a heart attack or stroke should aim for an LDL cholesterol of less than 55 milligrams per deciliter. The injectable PCSK9 drugs, alirocumab (Praluent) and evolocumab (Repatha), have been shown to reduce the incidence of heart attacks, strokes, and death from cardiovascular disease by up to 20% among people at high risk, over periods of up to at least five years. A similar study is currently underway to see if enlicitide offers the same benefit, with results expected in several years. Julie Corliss has been the executive editor of the Harvard Heart Letter since 2013. She also writes for the Harvard Health Letter, Harvard Women's Health Watch, and Harvard Men's Health Watch, as well as for Harvard... See Full Bio About the reviewer. Robert H. Shmerling, MD, Senior Faculty Editor, Harvard Health Publishing; Editorial Advisory Board Member, Harvard Health Publishing Dr. Robert H. Shmerling is the former clinical chief of the division of rheumatology at Beth Israel Deaconess Medical Center (BIDMC), and is a current member of the corresponding faculty in medicine at Harvard Medical School... See Full Bio Disclaimer: As a service to its readers, Harvard Health Publishing provides access to its library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.